First stage in Clinical research on FLARAXIN in 1991.
(Limited clinical approbation. Pre-clinical study of Flaraxin.
Development of the normative and technical documentation) in the KRIPT.
REPORT-1 on treatment of melanoblastoma at the different locations and stages (I phase of Clinical Trial).
REPORT-2 on treatment of advanced forms of melanoblastoma (II phase of Clinical Trial).
REPORT-3 on treatment of patients with lung, breast, cervical cancer and melanoblastoma (II ext.phase of Clinical Trial).
Colon Cancer Treatment by FLARAXIN.
Treatment of cervical cancer by FLARAXIN.
REPORT on Pathophysiological mechanisms of antitumor activity of FLARAXIN. Cand.Med.Sc., Assist.Prof. - Alexander Artemov
Physico-chemical properties of FLARAXIN.
Kinetics of the interaction between FLARAXIN and HSA.
REPORT on Enzyme activity of FLARAXIN and other preparations.
REPORT on Antiradical activity of FLARAXIN and therapeutic preparations of antitumor effect.
REPORT on influence of FLARAXIN and PROSPIDINE on the microviscosity of general lipids of erythrocytes.
REPORT on Cumulative properties of Flaraxin and acute toxicity of the base substance.
REPORT on Study of the effect of Flaraxin on immunological reactivity.
REPORT on Antioxidant properties of FLARAXIN and activity of aminotransferases in the blood of patients.
Pharmacokinetics of FLARAXIN.
Acute and chronic toxicity of FLARAXIN.
Experiment on C57B16 mice with melanoma B-16.
Antioxidant activity of Flaraxin at the initial stages of free radical oxidation.
Abstract ANTI-VIRTUAL SUBSTANCES PRESENT AND FUTURE
An abstract from the report on the treatment of mammary fibroadenomatosis.
Report on the treatment of mastopathy phytopreparations.
Treatment of bladder cancer.
Treatment of lung cancer.
Treatment of breast cancer.
Complex therapy of nonspecific vaginitis, combined with infection of the lower urinary tract.
Report on the effect of "Flaraxin" on endotoxicosis in advanced hormone-refractory prostate cancer.
Complex treatment of chronic bacterial prostatitis.